🧬 What current breakthroughs actually show
Recent research points to meaningful lifespan extension, not immortality:

- Rapamycin extends mouse lifespan by 15–20%, and combinations like rapamycin + acarbose reach 36.6% median lifespan extension.   
- GLP‑1 drugs (semaglutide, tirzepatide) are now considered gerotherapeutics because they improve metabolic, cardiovascular, and neurological aging pathways.   
- SGLT2 inhibitors became the first FDA‑approved class shown to lengthen telomeres and reduce senescent cells — two core hallmarks of aging.   
- Senolytics in 2026 Phase 2 trials reduced inflammation by 40–60% and improved mobility in older adults.   
- Partial cellular reprogramming (Yamanaka factors) is restoring youthful function in early human trials, including improved vision and tissue regeneration.  

These are huge steps — but they target healthspan, not immortality.

---

🧠 Why “living forever” is still out of reach
Even with breakthroughs, several barriers remain:

- Aging has 12+ interconnected hallmarks, and no single drug fixes them all.  
- Reprogramming risks cancer if not precisely controlled.  
- Genomic instability accumulates over decades and may not be fully reversible.  
- Organ failure and stochastic damage still occur even in long‑lived species.

In other words: we’re learning to slow and reverse parts of aging, but not eliminate it.

---

🌅 What is plausible in your lifetime
Based on current trajectories:

- Adding 10–20 healthy years is realistic.  
- Reaching 120–150 years is considered plausible by leading researchers.   
- Full biological rejuvenation (true age reversal) is being tested but not yet safe or complete.

So the future is exciting — but not “forever” yet.

---

🔍 If you want to explore a specific angle
Would you like to dive deeper into longevity drugs, reprogramming tech, or what living to 150 would actually look like?